Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation

Beijing, China

Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation

Beijing, China
SEARCH FILTERS
Time filter
Source Type

Liu Y.,Shenyang Pharmaceutical University | Liu Y.,Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation | Shi A.-X.,Shenyang Pharmaceutical University | Shi A.-X.,Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation
Chinese Journal of New Drugs | Year: 2017

Lifitegrast is a nonsteroial anti-inflammatory small molecule antagonist of the integrin lymphocyte function-associated antigen-1 (FDA-1), which mimics the binding epitope of ICAM-1, inhibits the interaction of LFA-1 and ICAM-1, and is indicated for the anti-inflammatory treatment of dry eye disease. In July 2016, lifitegrast was approved by the US FDA for improvement of both sign and symptom of dry eye disease. Clinical trials showed that the drug was safe and well tolerated. The main adverse reactions were instillation site irritation, dysgeusia and reduced visual acuity. In this article, the pharmacology, pharmacokinetics, clinical research and adverse reactions of lifitegrast ophthalmic solution were reviewed. © 2017, Chinese Journal of New Drugs Co. Ltd. All right reserved.


Xu S.,Beijing Hospital | Xu S.,Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation | Jin P.-F.,Beijing Hospital | Jin P.-F.,Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation | And 4 more authors.
Chinese Journal of New Drugs | Year: 2015

Literature analysis and review on the chemical substances illegally adulterated in traditional Chinese medicines and health foods were conducted, and the research advances on the adulterated chemical substances, the analytical methods and technical development directions as well as the supervision strategies were presented. The results indicated that the adulterated chemical substances mainly included sexual function enhancing drugs, sedative-hypnotic drugs, antidiabetic drugs, antiviral drugs, antibiotics, antipyretic drugs, analgesics and anti-inflammatory drugs, glucocorticoids, antitussive drugs, antihypertensive drugs, weight-loss drugs, and gastric acid secretion inhibiting drugs. The analytical methods involved the physico-chemical analysis, thin layer chromatography (TLC) analysis, high-performance liquid chromatography analysis, liquid chromatography-mass spectrometry analysis, gas chromatography-mass spectrometry analysis, capillary electrophoresis chromatography analysis, ion mobility chromatography analysis, infrared spectroscopy (including near-infrared spectroscopy) analysis and Raman spectroscopy analysis. Physico-chemical and TLC analysis could only be used for the preliminary screening. For the fast site analysis and screening, IR, RS and hollow fiber solvent microextraction-mobile HPLC are suitable choices. HPLC and LC-MS/MS techniques are suitable for the accurate laboratory screening and quantitative analysis. In addition to the development of analytical techniques, it is also very important to strengthen the supervisions of illegally adulterated chemical substances. ©, 2015, Chinese Journal of New Drugs Co. Ltd. All right reserved.

Loading Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation collaborators
Loading Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation collaborators